Purespring Therapeutics has successfully raised £80 million in an oversubscribed Series B financing round spearheaded by Sofinnova Partners. The company specializes in gene therapy and is focused on transforming the treatment of kidney diseases.
The company leverages a proprietary adeno-associated viral gene therapy platform to target podocytes, crucial cells in renal diseases, offering new modalities for disease-modifying treatments of various kidney diseases. It has a pipeline of several programs in development for conditions including nephrotic syndrome and glomerular kidney disease.
The primary investment focus will be developing Purespring’s lead program, which targets IgA nephropathy, or IgAN, a chronic kidney disease that predominantly affects young adults. The financing will help facilitate the initiation of a clinical trial for IgAN, underscoring Purespring’s commitment to addressing a significant health challenge.
